Agenus Completes Registered Direct Offering

  Agenus Completes Registered Direct Offering

Business Wire

LEXINGTON, Mass. -- September 23, 2013

Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously
announced agreement to sell $10 million of shares of its common stock,
together with warrants to purchase additional shares of its common stock, in a
registered direct offering to institutional investors. Agenus issued an
aggregate of 3,333,333 shares of its common stock at a price of $3.00 per
share along with warrants to purchase an additional 1,000,000 shares of its
common stock at an exercise price of $3.75 per share. The warrants are
exercisable six months after issuance and expire five years from the date on
which they become initially exercisable.

Separately, subsequent to June 30, 2013, Agenus has sold $11.7 million of its
common stock in at-the-market (ATM) offerings under its ATM facility.

Agenus intends to use the net proceeds from the offering for clinical trial
expenditures, research and development expenditures and potential acquisitions
of new technologies, as well as for working capital and general corporate
purposes.

H.C. Wainwright & Co., LLC acted as exclusive placement agent in connection
with the offering.

A shelf registration statement (File No. 333-185657) relating to the shares
issued in the offering has been filed with and declared effective by the
Securities and Exchange Commission (the “SEC”). A prospectus supplement
relating to the offering has been filed by Agenus with the SEC. Copies of the
prospectus supplement, together with the accompanying prospectus, can be
obtained at the SEC’s website at http://www.sec.gov, from request at H.C.
Wainwright & Co., LLC by e-mailing placements@hcwco.com, or from Agenus Inc.,
3 Forbes Road, Lexington, Massachusetts 02421.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities of Agenus in this offering. There shall not be
any offer, solicitation of an offer to buy, or sale of securities in any state
or jurisdiction in which such an offering, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction. Any offering will be made only by means of a
prospectus, including a prospectus supplement, forming a part of the effective
registration statement.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on immunotherapeutic
products based on strong platform technologies with multiple product
candidates advancing through the clinic, including several product candidates
that have advanced into late-stage clinical trials through corporate partners.
Between Agenus and its partners, 23 programs are in clinical development.

Additional Information

Statements made in this press release include forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, regarding,
but not limited to, the use of proceeds from the offering. Forward-looking
statements can be identified by the use of words such as “may,” “will,”
“plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or
comparable terminology. Such forward-looking statements are inherently subject
to certain risks, trends and uncertainties, many of which Agenus cannot
predict with accuracy and some of which Agenus might not even anticipate, and
involve factors that may cause actual results to differ materially from those
projected or suggested. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of Agenus’ Quarterly
Report on Form 10-Q for the quarter ended June 30, 2013, which was filed with
the SEC on August 9, 2013. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and Agenus
undertakes no obligation to update or revise the statements.

Contact:

Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and
Corporate Communications
jonae.barnes@agenusbio.com
 
Press spacebar to pause and continue. Press esc to stop.